ExpreS2ion Biotech Holding AB (OMXSTO:EXPRS2) Financings

ExpreS2ion Biotech Holding AB

Financings

RaiseDateIn US dollars
New shares on exercise of TO 13 warrants and directed issue to guarantor
Announced: SEK 19.3M–SEK 32.4M · SEK 1.6 a share · Vator Securities +2
Dealers: Vator Securities, SCHMIDT Capital Advisors, APREA Partners
Buyers: Vator Securities (guarantee undertaking totalling SEK 19.3 million); Alumni Capital; Tellus Equity AB; Leif Helth Jensen; John Haurum; Thomas Larsson
Use of proceeds: Complete the ES2B-C001 Phase I study, strengthen licensing negotiations, platform and CMC development, and business development
Sep 14, 2026US$1.98M
New shares under put option agreement
Announced: up to SEK 50M
Buyers: Alumni Capital Limited (commitment of up to SEK 50,000,000 in equity financing over 24 months)
Sep 14, 2026US$5.12M
Rights offering of units consisting of new shares and warrants of series TO 13
Closed: SEK 31.8M raised · SEK 1.6 a unit · warrants of series TO 13 issued free of charge, exercisable at a price corresponding… · Schmidt Capital Advisors +1
Dealers: Schmidt Capital Advisors, Vator Securities
Buyers: Bent U. Frandsen (part of board and management subscription commitments totalling approximately SEK 0.7 million)
Insiders: Board members and management, including CEO Bent U. Frandsen, gave subscription commitments totalling approximately SEK 0.7 million, about 1.3 percent of the Rights Issue
Use of proceeds: Continue executing the prioritised strategy and support the Company through the period leading up to the TO 13 warrant exercise window
May 4, 2026US$3.43M

Read by 6ix AI from the company's releases